Biohaven Funds Phase 3 IgG Degrader Without Clinical Proof or Precedent

Biohaven Licenses Extracellular IgG Degraders to Ono Pharma for Asia

Biohaven Ltd. has announced a strategic licensing and collaboration agreement with Ono Pharmaceutical Co., Ltd. for its MoDE pan IgG degrader portfolio, including lead candidate BHV-1300, in Japan, South Korea, Taiwan, and the ASEAN region. Under the terms, Biohaven will receive up to $100 million in near-term payments, comprising an $80 million upfront payment and a $20 million milestone payment within a year, plus approximately twenty percent royalties on net sales. Biohaven retains all rights outside this licensed territory, including in the US, Europe, and China. BHV-1300, an investigational small-molecule extracellular IgG degrader, is currently in Phase 3 development for Graves' disease, with potential for other IgG-mediated autoimmune conditions.

• Biohaven will receive significant financial consideration, including an $80 million upfront payment and an additional $20 million milestone payment anticipated within one year, totaling up to $100 million in near-term payments. This non-dilutive capital provides substantial long-term upside for shareholders and supports Biohaven's ongoing development efforts.
• The agreement grants Ono Pharmaceutical exclusive rights to develop and commercialize Biohaven's MoDE pan IgG degrader portfolio, including BHV-1300, BHV-1310, and BHV-1320, across Japan, South Korea, Taiwan, and the ASEAN region. Biohaven strategically retains all rights to the portfolio in other key global markets, including the US, Europe, and China, ensuring broad market potential.
• The lead candidate, BHV-1300, is an investigational small-molecule extracellular IgG degrader currently in pivotal Phase 3 development for Graves' disease. It is designed to selectively target and remove pathogenic IgG1, IgG2, and IgG4 autoantibodies while sparing IgG3, offering a differentiated profile with rapid onset, deep lowering, and patient-friendly subcutaneous self-administration.

Biohaven's MoDE Portfolio: Beyond Graves' Disease

The knowledge base does not have sufficient information to answer this question.

BHV-1300's Safety and Efficacy Profile in Autoimmune Diseases

The knowledge base does not have sufficient information to answer this question.

Navigating the Evolving Graves' Disease Treatment Landscape

Paradigm shifts have occurred in the management of uncomplicated Graves' disease and its variants, with antithyroid drugs (ATDs) now the preferred mode of therapy. The preferred mode of therapy for uncomplicated GD was antithyroid drugs (ATDs) by 91.5% of respondents, radioactive iodine (RAI) therapy by 7%, and thyroidectomy by 1.5%, with the use of RAI as a first-line choice decreased in all geographic regions and The U.S. had the sharpest decline in the selection of initial therapy with RAI, decreasing from 69% in 1990 to 11.1% in 2023. Continuous ATD treatment for ≥60 months is more effective in inducing sustained long-term euthyroidism, with long-term treatment with continuous methimazole (≥60 months) resulting in substantially higher sustained remission (<20% relapse) compared with conventional ATD courses (approximately 50% relapse), producing faster normalization of TSH, greater time spent in euthyroidism, fewer orbitopathy exacerbations, and minimal late adverse events. In patients with persistent TRAb positivity after 18 months, 68.7% of respondents would continue the use of ATDs, and after a relapse of GD, resumption of ATDs was selected by 59.9% of respondents.

TED management is shifting to an era of targeted therapy with multidisciplinary care, spearheaded by teprotumumab, an IGF-1R-inhibiting monoclonal antibody. Randomized clinical trials demonstrating the efficacy of teprotumumab for TED led to Food and Drug Administration approval, and Teprotumumab is gradually replacing immunosuppressive agents as first-line therapy in the United States for active moderate-to-severe TED. Teprotumumab, a human monoclonal antibody that blocks IGF-1R without binding to TSHR, has been shown to significantly improve outcomes in moderate-to-severe TED, including greater proptosis reduction compared with intravenous methylprednisolone, with remarkable improvement in terms of disease activity, proptosis, and diplopia. Its disadvantages include side effects (eg, hearing loss in 30% of patients), a high cost, and a high relapse rate, while Tocilizumab, which blocks the interleukin-6 receptor, is an effective treatment option for patients with TED who are steroid-resistant, and Mycophenolate significantly increased the overall response rate combined with standard glucocorticoid (GC) treatment compared to GC monotherapy.

Immunotherapies of GH have recently demonstrated clinical efficacy in preliminary studies, including ATX-GD-59, an antigen-specific immunotherapy which restores immune tolerance to the thyrotropin receptor; iscalimab, an anti-CD40 monoclonal antibody which blocks the CD40-CD154 costimulatory pathway in B-T cell interaction; and K1-70, a thyrotropin receptor-blocking monoclonal antibody. In young people (ages, 12-20 years) with Graves hyperthyroidism receiving 500 mg rituximab and 12 months of ATD titrated according to thyroid function, Thirteen of 27 participants were in remission at 24 months (48%, 90% one-sided CI, 35%-100%), with B-lymphocyte count at 28 weeks, expressed as a percentage of baseline, related to likelihood of remission.

Biohaven's IgG Degrader: A New Frontier in Autoimmune Treatment

The recent licensing agreement for Biohaven's MoDE pan IgG degrader portfolio, spearheaded by lead candidate BHV-1300, marks a significant strategic move in the competitive autoimmune disease space. This deal, covering key Asian markets, not only provides substantial non-dilutive capital but also validates the potential of a novel small-molecule approach to degrading extracellular IgG. With BHV-1300 currently in Phase 3 for Graves' disease, its success could pave the way for a new class of therapeutics addressing a wide array of IgG-mediated autoimmune conditions.

The landscape for these diseases, including myasthenia gravis, immune thrombocytopenia, and Guillain-Barré syndrome, is characterized by a persistent unmet need for more effective and convenient treatments. While traditional interventions like plasmapheresis and intravenous immunoglobulins offer acute relief, they are often burdensome and associated with adverse events. The emergence of FcRn antagonists has provided a new paradigm by selectively reducing pathogenic IgG, demonstrating strong clinical efficacy. However, a small-molecule degrader like BHV-1300 could offer distinct advantages, potentially including oral administration or a more favorable safety profile compared to some existing biologics or broad IgG-degrading enzymes, which have shown risks of profound hypogammaglobulinemia.

However, the path forward is not without its challenges. The primary risk lies in the ongoing Phase 3 clinical trials; positive outcomes are crucial for market entry and differentiation. The competitive pressure from established and pipeline FcRn antagonists will necessitate a clear demonstration of BHV-1300's unique benefits. Furthermore, as an IgG degrader, careful monitoring for any potential impact on overall immune function will be paramount. Should BHV-1300 prove safe and effective, this collaboration could accelerate its global reach, offering a promising new option for patients suffering from chronic autoimmune conditions and reshaping treatment paradigms.